HWP
TEVA icon

Highline Wealth Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Highline Wealth Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.56K Hold
46
– – ﹤0.01% 1216
2026
Q1 		$1.39K Hold
46
– – ﹤0.01% 1117
2025
Q4 		$1.44K Hold
46
– – ﹤0.01% 887
2025
Q3 		$929 Sell
46
-119
-72% -$2.09K ﹤0.01% 935
2025
Q2 		$2.77K Hold
165
– – ﹤0.01% 578
2025
Q1 		$2.54K Buy
+165
New +$2.95K ﹤0.01% 587

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Highline Wealth Partners's TEVA Position: Q2 2026 in Review

Highline Wealth Partners held its Teva Pharmaceuticals (TEVA) position steady in Q2 2026 at 46 shares worth $1.56K. The position accounts for ﹤0.01% of the portfolio, ranked #1216.

Highline Wealth Partners first reported a position in TEVA in Q1 2025 and has held it in 6 quarters since. The position peaked at $2.77K in Q2 2025. 675 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Highline Wealth Partners held 46 shares of Teva Pharmaceuticals worth $1.56K as of Q2 2026.
  • Highline Wealth Partners left its Teva Pharmaceuticals share count unchanged in Q2 2026.
  • Teva Pharmaceuticals made up ﹤0.01% of Highline Wealth Partners's portfolio in Q2 2026, its #1216 holding.
  • Highline Wealth Partners first reported a position in Teva Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • Highline Wealth Partners's Teva Pharmaceuticals position peaked at $2.77K in Q2 2025.
  • 675 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Highline Wealth Partners's 13F filing for Q2 2026, filed 15 Jul 2026.